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Abstract
Background: Governments and other payers are yet to determine optimal processes by which to review the safety,
effectiveness, and cost-effectiveness of technologies and procedures that are in active use within health systems,
and rescind funding (partially or fully) from those that display poor profiles against these parameters. To further
progress a disinvestment agenda, a model is required to support payers in implementing disinvestment in a
transparent manner that may withstand challenge from vested interests and concerned citizens. Combining
approaches from health technology assessment and deliberative democratic theory, this project seeks to determine
if and how wide stakeholder engagement can contribute to improved decision-making processes, wherein the
views of both vested and non-vested stakeholders are seen to contribute to informing policy implementation
within a disinvestment context.
Methods/design: Systematic reviews pertaining to illustrative case studies were developed and formed the
evidence base for discussion. Review findings were presented at a series of deliberative, evidence-informed
stakeholder engagements, including partisan (clinicians and consumers) and non-partisan (representative
community members) stakeholders. Participants were actively facilitated towards identifying shared and dissenting
perspectives regarding public funding policy for each of the case studies and developing their own funding
models in response to the evidence presented. Policy advisors will subsequently be invited to evaluate
disinvestment options based on the scientific and colloquial evidence presented to them, and to explore the value
of this information to their decision-making processes with reference to disinvestment.
Discussion: Analysis of the varied outputs of the deliberative engagements will contribute to the methodological
development around how to best integrate scientific and colloquial evidence for consideration by policy advisors. It
may contribute to the legitimization of broad and transparent stakeholder engagement in this context. It is
anticipated that decision making will benefit from the knowledge delivered through informed deliberation with
engaged stakeholders, and this will be explored through interviews with key decision makers.
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Disinvestment as a policy approach to healthcare safety
and quality
As health system managers increasingly seek ways in
which to improve quality of care and constrain resource
use, the concept of health technology reassessment with
potential for disinvestment has gained currency. Having
existed for some time in the realms of business and
manufacturing, the consideration of disinvestment prac-
tices within healthcare is relatively new, with antece-
dents in evidence-based medicine (EBM) and health
technology assessment (HTA). Disinvestment seeks to
improve health outcomes by evaluating existing health
services, identifying those that do not provide safe, ef-
fective, or cost-effective care, and redirecting funding
away from these services and towards those with super-
ior safety, effectiveness, and cost-effectiveness profiles
through a variety of policy approaches [1,2]. It does not
by definition need to be a dichotomous choice to fund
or not to fund; disinvestment can occur by degrees,
whereby subsidies may be restricted to subgroups of
patients for whom there is evidence of potential for
benefit based on specific clinical characteristics (referred
to as ‘refining the indications’ for service provision).
While there has been international interest in dis-
investment, it remains an essentially theoretical con-
struction that has only been operationalized in a limited
manner in few jurisdictions [3]. A number of challenges
are faced in developing and implementing the concepts
of disinvestment into pragmatic policy approaches.
While methods for the assessment of new and emerging
technologies and services have become relatively well-
established in the processes of HTA, governments and
other payers are still to determine the optimal processes
by which to review existing technologies and procedures.
Often these pre-date the EBM and HTA era and thus
have escaped rigorous evaluation of safety, effectiveness,
and cost-effectiveness, yet are entrenched as offerings
within healthcare.
In considering processes for refining funding for estab-
lished technologies and services, contested elements may
include: what is counted as ‘evidence’ and by whom; the
‘burden’ of evidence required; and the consultative compo-
nents that may be necessary to support disinvestment deci-
sions. A best-practice model to support payers in pursuing
explicit efforts towards disinvestment in a manner that
may withstand challenge from vested interests and inter-
ested citizens is yet to emerge [1].
With a view to bridging this divide between policy and
practice, a competitively funded, Australian-based re-
search project was established in 2009. The purpose of
the ASTUTE Health study (Assessing Service and Tech-
nology Use To Enhance Health) is to develop, trial, and
evaluate a transparent process by which to refine the
indications for services, to ensure investment in proce-
dures with favourable safety, effectiveness, and cost-
effectiveness profiles. Independent of government, this
multidisciplinary project seeks to incorporate methods
from HTA and deliberative democratic theory and, as
such, represents a novel approach to the development of
evidence-based health policy wherein the views of both
vested and non-vested stakeholders are seen to contrib-
ute valuably and uniquely to informing policy decisions
within a disinvestment context.
Deliberative democracy: Involving the community
Deliberative democratic methods have gained prominence
in recent years, driven in part by the rise of evidence-
informed policy-making and the potential for these meth-
ods to assist in involving the broader community in demo-
cratic governance that extends beyond voting [4,5].
Current methods of policy development and decision mak-
ing are considered to contain democratic deficits, created
by the opaque, but often dominant roles of strong special
interest groups/experts, an inability to represent heteroge-
neous public interests, and a lack of processes by which to
encourage input from adequately informed members of
the general public [6,7]. Additionally, there remains a need
for ‘health services to be accountable to users as taxpayers,
voters, and consumers’ [8].
Debate around ‘the fair and reasonable allocation of
resources has become a prominent one in modern day
discourses about healthcare’ [9]. Health funding deci-
sions, particularly those which relate to some level of re-
imbursement retraction (more effective redistribution
notwithstanding) may carry significant moral implica-
tions, be highly contested (by a range of stakeholders)
and historically have not been made in an explicit and
transparent manner. The complexity and contestability
inherent in disinvestment decisions position such health
policies as key candidates for the integration of delibera-
tive methods in their construction [4].
Within this study, members of the community will be
involved in making explicit the barriers and facilitators
of disinvestment (with reference to both the specific case
studies and the broader disinvestment context), and to
determine whether stakeholder engagement could con-
tribute to creating improved and transparent decision-
making processes in this policy domain. Additionally, it
is anticipated that the colloquial evidence collected from
community members will enhance the scientific evi-
dence base derived from the systematic reviews, and bal-
ance the perspectives of other more actively vested
stakeholders and special interest groups.
Experiential knowledge: involving vested stakeholders
In order to align this research project with the realities
of policy making, to which a wide variety of stakeholders
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vested stakeholders (clinical and consumer groups) will
also be included in addition to the views of non-partisan
citizens. This broad, evidence-informed engagement
seeks to mimic and enhance the diverse range of inputs
with which health policy decision-makers must grapple
in the course of negotiating health policy development;
such inputs have not always been transparent. Greater
accountability in decision making will be supported by
the structured frame of discussion offered by a process
of facilitated deliberation around an evidence base.
Health resource allocation decisions also may need to
go beyond a narrow scientific view of evidence and con-
sider ‘colloquial’ evidence [4] alongside scientific evi-
dence. Deliberative and other consultative processes may
usefully be employed to combine these different kinds of
evidence to increase the likelihood of achieving ‘sound
and acceptable decisions’ (Stern et al. in [4]). By includ-
ing clinical and consumer groups in these processes, it is
anticipated that critical experiential knowledge will be
added to the scientific evidence collected through sys-
tematic review.
Herein, we describe the implementation of methods
for broad stakeholder deliberative engagements, a frame
for evaluation, and a costing of the process.
Methods/design
Overview of the study design
Two case studies were selected for the project: assisted
reproductive technologies (in vitro fertilization (IVF) and
intracytoplasmic sperm injection (ICSI) with specific
reference to the safety, effectiveness, and cost-
effectiveness related to female age, male age, and cycle
rank); and vitamin B12 and folate pathology tests. The
services/procedures associated with both of these case
studies are publicly subsidised under Australia’s universal
health insurance scheme, Medicare.
The first phase of the project (see Figures 1 and 2)
entailed systematic reviews for each case study. These
reviews demonstrated the variable effectiveness profiles
associated with both assisted reproductive technologies
(ART) and B12/folate tests [10,11], and collated a wide
range of evidence for stakeholders to consider, including
ethical and costing analyses.
In the second phase, the findings of these reviews will
be presented at a series of deliberative, evidence-
informed stakeholder engagements designed to include
both motivated stakeholders who have traditionally
dominated health policy development (clinicians and
consumers) and also the voice of the ‘average citizen’
which is often not heard or excluded from policy
decision-making [7]. Each of the stakeholder groups will
be actively facilitated towards identifying both shared
and dissenting perspectives regarding public funding
policy for each of the case studies in response to the evi-
dence presented.
Finally, in phase three, policy advisors will be pre-
sented with the results of the reviews, alongside the per-
spectives of all the stakeholder groups collected in phase
two. They will be invited to formulate a disinvestment
opinion based on both the scientific and colloquial evi-
dence presented to them, and then to explore their
decision-making processes and rationale with reference
to the disinvestment context.
The remainder of this paper will focus on project phases
two and three as these represent the novel components of
the process. A description of the systematic reviews and
their findings has been published elsewhere [10,11].
Selection of case studies
The two case studies of ARTand pathology testing for vita-
min B12 and folate were considered to elucidate an under-
standing of the broader issues surrounding the
development of disinvestment policy [12]. Both were iden-
tified as candidates for further assessment under disinvest-
ment initiatives because they met multiple criteria on a
proposed identification framework [1], including substan-
tial temporal and geographic variation in usage and early
evidence of differential effectiveness across patient sub-
groups. Additionally, the case studies were considered to
engender a variety of different demands on a disinvestment
process and were selected in part for their illumination of
different potential responses from stakeholders. The ART
case study was considered more likely to draw strongly on
values-based arguments in the face of relatively low but ris-
ing volumes and high cost, while the vitamin B12/folate
testing case study represented an ostensibly non-controver-
sial, low-cost service, albeit one with high and rising
utilization.
To this end, the case studies were selected: to meet the
dual goals of research and policy development; to create an
innovative approach to shared decision-making; to evaluate
the feasibility of participatory processes involving a wide
range of stakeholders; and to learn about how these groups
perceive disinvestment processes in the context of
evidence-informed deliberation.
Designing evidence-informed deliberative stakeholder
engagement
The deliberative engagements for each case study were
designed and piloted by a multidisciplinary team (includ-
ing clinical advisors). Ethics approval for all arms of this
study was obtained from The University of Adelaide’s
Human Research Ethics Committee.
The case studies were undertaken in a staggered pro-
gression to allow for refinement of the process with ex-
perience: ART was examined first, followed by the B12/
folate case study.
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a power balance, and to cater for differing levels of expert-
ise, stakeholders were consulted in separate engagements.
Potentially partisan stakeholders were not mixed with lay
citizens, but the ideas generated by each group were com-
municated to the subsequent groups to share knowledge
and allow cumulative solutions to be constructed.
Recruitment
Methods of recruitment for the engagement sessions
varied between the groups and are detailed in Table 1,
with recruitment strategies constructed to take into ac-
count the objectives of each deliberative event alongside
considerations of feasibility.
Participants in the clinical, consumer, and policy
groups were purposively recruited on the basis of their
experiential knowledge, stature as opinion-leaders, and
role in decision-making processes. Nominations for clin-
ical participants were sought from key stakeholder bod-
ies in the respective fields of reproductive medicine and
pathology. Nominees were then approached with a letter
of invitation, as were key practitioners in each field.
Systematic review
Safety & effectiveness with 
reference to female age, 
male age & cycle rank
Ethical analysis
Constructions of need; 
capacity to benefit, equity
Health policy 
Policy making process, 
history, international 
comparisons
Economics
Differences in marginal cost 
by age & cycle rank
Phase 1: 
Evidence reports
Round II: Development of consensus/majority funding models 
(incorporating outcomes of Round I & extra evidentiary requests)
Community Clinicians Consumers
Policy advisors (Federal)
Phase 3:
Policy deliberation & analysis  
Process evaluation
Policy advisors (State & Federal)
Clinicians Consumers Community
Round I: Canvassing range & diversity of opinion
Phase 2: 
Stakeholder engagement
Figure 1 Process of ART case study.
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vertisement placed in the highest-circulating daily news-
paper in South Australia. Due to the ubiquity of the test,
an appropriate consumer group for the B12/folate case
study could not be identified.
Policy advisors across portfolios, divisions, and
branches (state and federal) directly related to health
funding were approached by the project’s Chief Investi-
gators and invited to participate in the evaluative com-
ponent of the project, with further policy participants
identified through snowballing.
Recruitment of community members sought partici-
pants descriptively representative of Australian popula-
tion demographics, although it is acknowledged that
such a small sample cannot be completely statistically or
politically representative [13]. Pre-determined stratifica-
tion criteria (gender, age, household income) were ap-
plied by an independent recruitment company to a
randomly sampled group of South Australian residents,
thus avoiding oversampling from older or more
economically-advantaged groups.
Sample sizes for the community engagements were
based on those advocated for citizen’s juries [14-17],
while the other engagements were slightly smaller,
reflecting the specificity of recruitment requirements.
These were particularly rigorous for the ART case
study, because the sensitivity of the topic under discus-
sion required exclusion criteria designed to minimise
any potential harm to participants. We felt a duty of
care towards consumers who had not been able to
achieve a successful live birth because this can be the
source of much ongoing distress. The sample sizes
were considered optimal to deliver a diversity of opi-
nions while still allowing full and active participation
in ‘communicative processes and will-formation’ [18].
From a research perspective, the sample sizes were
sufficient to test the logistical and practical compo-
nents of the engagement design [6], while also evaluat-
ing the benefits and drawbacks of the use of
deliberative engagements in future decision making be-
yond the bounds of research.
Structure of the deliberative engagements
The two case studies differed in their structure for a
number of reasons. The ART case study engaged each
stakeholder group in two ‘rounds’; this was designed to
Community:
Role of testing; 
expectations; value of 
test with uncertain 
evidence base
Specialists:
Exploration of 
utilisation; evidence; 
potential for change
General 
Practitioners (2):
Exploration of evidence; 
potential for change
General 
Practitioners (1)
Exploration of 
utilisation; evidentiary 
requests
Pathology 
providers:
Exploration of 
utilisation; evidence; 
potential for change
Phase 2: 
Stakeholder engagement
Policy advisors (Federal)
Phase 3:
Policy deliberation & analysis  
Process evaluation
Utilisation
Examination of Medicare 
data to determine basic 
utilisation patterns
Pathology audit
Examination of routinely 
collected laboratory data to 
determine B12/folate test 
positivity rates
Systematic review
Diagnostic accuracy of
B12/folate tests 
Guideline review
Identification & 
examination of advice 
provided by current clinical 
practice guidelines 
Phase 1: 
Evidence reports
Figure 2 Process for vitamin B12/folate pathology testing case study.
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Stakeholder
group
Sample size Method/s of recruitment Selection and exclusion criteria Demographics
Case study 1: assisted reproductive technologies
Clinicians Recruited: N = 19 Nominations from key representative
bodies in the field of reproductive
medicine*; purposive sampling of
key opinion leaders; snowballing
Medically qualified clinicians working
in ART and associated fields such as
maternal/fetal medicine and
neonatology
4 males; 4 females
Role and practice
†:
Reproductive medicine:
5/8
Participated: Round I N = 8 Exclusion criteria: Other (including
obstetrics/gynaecology
and neonatology): 3/8 Participated Round II N = 6 - Participants and/or their partners who
had undertaken ART in the 3 years
immediately preceding the forum
- Participants currently undertaking ART
treatment or planning to undertake
ART in the foreseeable future
Consumers Recruited: N = 32 Purposive recruitment seeking
participants with a broad range of ART
experiences - advertisement seeking
participants placed in The Advertiser
(Adelaide’s daily newspaper). Detailed
topic and exclusion criteria
‡
- Females 18 years and older who had
undertaken ART treatment, regardless
of infertility aetiology
1 male; 8 females
Participated: Round I N = 9 - Up to 3 males, partners of women
who had undertaken ART
Participated: Round II N = 7 Exclusion criteria:
Reason for exclusion: - Participants and/or their partners who
had undertaken ART in the 3 years
immediately preceding the forum Withdrew interest: 2
Unable to contact
further: 4
Unable to attend:1 - Participants currently undertaking ART
treatment or planning to undertake
ART in the foreseeable future Related to other
participant: 1
ART undertaken <3
years prior: 12
- An inability to speak and read English
Currently undergoing
ART: 1
- Pregnant women
Community Recruited: N = 25 Random sample of SA population,
identified and contacted by
independent recruitment company
18 years or older; matched against
predetermined stratification criteria for
broadly proportional representation
of the Australian population
§
7 males; 7 females
Exclusion criteria: Age:
Participated: Round I N = 14 6 participants had previously
participated in a separate citizens’ jury
- Participants currently undergoing ART
or who had undergone ART
18-30: 4/14
Participated: Round II N = 10 - Participants planning to undertake
ART in the foreseeable future
31-40: 1/14
Reasons for exclusion: - An inability to speak and read English 41-50: 3/14
Withdrew interest: 5 51+: 6/14
Missed recruitment
deadline: 5
- Pregnant women Post-tax income:
<AU$800/week: 7/14
Did not meet inclusion
criteria: 1
>AU$800/week: 7/14
Case study 2: B12 and folate pathology tests
Clinicians:
General
Practitioners
Recruited: N = 26 Letters of invitation sent to all GPs
from 4 South Australian Divisions of
General Practice (Adelaide Hills;
Adelaide Western; Adelaide Northern’
Yorke Peninsula); respondents selected
on ‘first-come’ basis with 2 places
reserved for GPs from regional areas
Registered GP working part-time or
full-time in active practice in
South Australia
9 males; 5 females
Participated: N = 14
Reasons for exclusion:
Withdrew interest: 4
Quota filled: 8
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tionally complex nature of the topic. It also allowed the
opportunity for each group to hear the perspectives of
the other stakeholders, and question, incorporate, or dis-
card those views as they deliberated further.
Consumer engagements for the ART case study were
approximately four hours long, and held on a mid-week
evening over dinner. They included short evidence pre-
sentations and a wide-ranging participant deliberation.
Sessions were designed to build from participants’
experiences, allowing them to extrapolate to consider
broader implications for the healthcare system.
The process for the B12/folate case study was stream-
lined, with general practitioners (equivalent to primary
care physicians) the only group consulted twice. With
the largest proportion of pathology test requests in Aus-
tralia arising from primary care [19], it was considered
critical to place significant emphasis on interaction with
general practitioners in order to ascertain their views on
the tests, the evidence, and the potential for change
through the lens of primary care. The practicalities of as-
sembling national-level stakeholders across multiple
rounds for the purposes of the research precluded a sec-
ond round of engagement.
The deliberative engagements for clinicians (specialists,
general practitioners, and pathology providers) were
designed to incorporate their significant experiential know-
ledge. Four-hour sessions, drawing on existing knowledge
and experience of participants, included short evidence
presentations and a meal, allowing approximately three
hours of participant deliberation. The majority of these ses-
sions were held in the state of South Australia, with only
the pathology provider engagement taking place in another
state (New South Wales; due to the participants being
nominated by their national-level organisation).
The community engagements were held over two days
(non-consecutive for ART; consecutive for the B12/folate
case study), designed to allow time for information shar-
ing, deliberation, and relationship building, acknowledg-
ing that the participants were not content experts.
Table 2 details the structure for each of the sessions, all
of which included a variety of information presentation
(adapted for the informational needs of each group),
group activities, and deliberation. In all groups,
Table 1 Details of recruitment processes and outcomes (Continued)
Clinicians:
Specialists
Recruited: N = 7 Purposive sampling with key
practitioners sent letter of invitation;
snowballing.
Participants must be registered specialist
practitioners (including, but not limited
to: geriatricians, physicians,
endocrinologists and haematologists)
working full-time or part-time in active
practice in South Australia
4 males; 2 females
Speciality:
Participated: N = 6 General physician: 3/6
Reasons for exclusion:
Withdrew interest: 1
Endocrinologist:1/6
Haematologist: 2/6
Pathology
providers
Recruited: N = 9 Nominations from national public and
private pathology interest groups
ǁ;
purposive sampling of key opinion
leaders; snowballing
Participants must be working full-time
or part-time in administrative,
management or laboratory roles in
private or public pathology providers
in Australia
5 males; 3 females
Participated: N = 9 Role and practice:
Public pathology: 2/8
Private pathology: 5/8
Management: 1/8
Community Recruited: N = 16 Random sample of SA population,
identified and contacted by
independent recruitment company
18 years or older; matched against
predetermined stratification criteria
for broadly proportional representation
of the Australian population
§
5 males; 6 females
Age:
Participated: N = 11 18-30: 3/11
Reasons for exclusion:
Withdrew interest: 5
31-40: 2/11
41-50: 3/11
51+: 3/11
Post-tax income:
<AU$800/week: 5/11
>AU$800/week: 6/11
NOTES: ART assisted reproductive technologies; GP general practitioner; SA South Australia.
*including the Australian Medical Association; Royal Australian and New Zealand College of Obstetricians and Gynaecologists; Royal Australian College of
Physicians; Royal Australian College of General Practitioners; Fertility Society of Australia.
†Many of the reproductive medicine specialists held dual qualifications/clinical roles in gynaecology.
‡Copy available from the authors on request.
§Stratification criteria based on national Australian Bureau of Statistics data and included: gender (50:50 male:female ratio); age (equal representation from 4 age
groups: 18–30; 31–40; 41–50; 51+); and household disposable income (post-tax) (50:50 household income <:>$800.00 per week).
ǁ including National Coalition of Public Pathology, Australian Association of Pathology Practices; Australasian Association of Clinical Biochemists; Healthscope;
Sonic; and Primary Health.
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vitamin B12 and folate
Assisted reproductive technologies:
Day 1
Objectives: Specific Activities:
Share knowledge regarding health policy in Australia, assisted reproductive
technologies and frameworks for decision-making.
Welcome, introductions and orientation (large group)
Explore preliminary responses and construct funding criteria. Presentations and questions: health policy in Australia, ART safety
and effectiveness (large group); costs; ethical frameworks (100 minutes;
large group)
Activity and discussion: International comparisons to identify perceived
strengths and weaknesses of different funding models (40 minutes;
large group)
Activity and deliberation: Construct exhaustive list of possible criteria
that could be used to restrict funding for ART (large group); refine this
list (small groups) and vote on top 5 criteria that should and should not
be considered for imposing funding restrictions (individuals) (total 90
minutes)
Discussion: other information required to construct funding
scenarios (30 minutes; large group)
Day 2
Objectives: Specific Activities:
To determine if the criteria for the public funding of ART should be
changed; why; and how
Presentation and questions: information requested after day 1
(15 minutes; large group)
Presentation and questions: summary of findings from other
stakeholders (15 minutes; large group)
Activity: Construction of funding scenario (45mins; individual/pairs)
Activity and deliberation: Consensus building on funding scenarios (75
minutes; large group)
Debrief and close
Pathology testing for vitamin B12 and folate:
Day 1
Objectives: Specific Activities:
To determine what considerations should be taken into account when
making decisions about how B12/folate pathology tests are publicly
subsidised
Discussion: experience and expectations as healthcare
consumers (50 minutes; large group)
Presentation and questions: pathology in General Practice;
defining the policy context (75 minutes; large group)
Discussion: Responding to utilization changes (45 mins; large group)
Activity and participant questions: General testing epidemiology (60
minutes; large group)
Day 2
Objectives: Specific Activities:
To determine what considerations should be taken into account when
making decisions about how B12/folate pathology tests are publicly subsidised
Presentation/questions: B12/folate testing (30 minutes; large group)
Presentation and questions: Rise in level of B12/folate testing and
stakeholder responses (15 minutes; large group)
Activity and deliberation: What things should be considered when making
decisions about how much we should publicly subsidise B12/folate
pathology tests? List of factors for consideration (large group); determine
5 most important factors (small group); consensus building activities
(large group) (total 150 minutes)
Debrief and close
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large and small group brainstorming, small group dis-
cussion, and open discussion. Experts who had pre-
sented information (including a general practitioner,
pathologist (B12/folate case study), ethicist (ART case
study), and research staff) were available for questioning
on points requiring clarification or to further inform,
but did not take part in deliberations.
In line with the evaluative nature of these engage-
ments, phase three sessions with the policy makers will
be structured around a presentation of the evidence base
and discussion of the responses from stakeholders, fol-
lowed by a set of open-ended questions that will allow
them to explore the outcomes, strengths, weaknesses,
and overall value of the process from a policy perspec-
tive. The two-hour roundtable sessions will be held in
the Australian Capital Territory and South Australia,
and commence with an overview of the project’s out-
comes. Participants will be encouraged to engage in an
open dialogue regarding each of the specific case studies
and a reflection on the nature of disinvestment policy
more broadly constructed.
Evidentiary and other inputs
For both of the case studies, the majority of information
presented to the participants was based on systematic
reviews of the relevant literature that were specifically
commissioned as a component of this research [10,11].
These were supplemented with information modules per-
taining to other relevant aspects of health funding deci-
sion-making, including: description of the technology/
procedure; an overview of health funding policy in
Australia (complete with Medicare cost and utilisation data
by location and demographics) and elsewhere; economic
considerations [20]; and broad ethical frameworks to sup-
port decision-making [21] (see Figures 1 and 2).
Prior to the roundtable discussions, clinical participants
were provided with a brief summary of the topic and a
broad indication of the context for the discussion. At each
session, expert members of the research group presented
the information modules described above and remained
available for questioning for the duration of the evening.
Participants in the consumer engagement (ART case
study) were told the topic and context for discussion
prior to the engagements, but were not provided with
any detailed information. Evidentiary inputs were limited
in the first round of engagement, which focussed on
international variation in ART funding and previously
proposed changes to ART funding in Australia. The sec-
ond round of engagement included a brief presentation
on age-specific safety and effectiveness, alongside the
perspectives of other stakeholder groups and the funding
models that they had constructed.
Based on multiple reports of lay citizens engaging suc-
cessfully in technically complex areas of health policy
[22-24], this process of community engagement was
designed around evidence-informed deliberations, re-
quiring participants to be technically informed on a
topic without influencing their deliberation [5]. For the
community groups in each case study, the information
presented was designed to be accessible to participants
with no prior knowledge of the topic areas.
Aware that the topic of ART can engender highly emo-
tional reactions, written versions of the information
modules designed to be accessible to a lay audience were
distributed one week prior to the engagement session to
allow participants the chance to consider their views on
the public funding of ART before entering into a poten-
tially evocative group deliberation. This was not consid-
ered necessary for the B12/folate case study due to its
relatively more benign characteristics.
During these sessions there were a number of presen-
tations from expert witnesses with regard to: current
Australian health funding policies; safety and effective-
ness parameters of the technologies; and economic [20]
and ethical considerations [21] (see Table 2). Details of
the clinical application of ART were also presented, and
the B12/folate case study included educative components
related to the interpretation of test characteristics (e.g.,
diagnostic accuracy as measured by sensitivity and speci-
ficity) and clinical aspects of test ordering. The speakers
who presented each of these sessions remained available
to answer questions during subsequent deliberations.
Policy advisors will be provided with a detailed briefing
paper one week prior to the session, providing an overview
of the systematic review and summary points from each
stakeholder engagement. Brief presentations will be pro-
vided by senior research staff, who will remain available to
answer questions and provide clarification on any points
for the remainder of the engagement session.
Facilitation
Clinical, community (citizen), and consumer (patient)
engagement sessions were facilitated by an independ-
ent and neutral facilitator, who was not involved in
participant deliberation or questioning of experts (ex-
cept on points of clarity) and did not provide expert
information. The facilitator managed the group interac-
tions, ensuring that all participants had the opportun-
ity to be heard; encouraged in-depth discussion and
negotiation amongst the participants; and assisted par-
ticipants in identifying areas of consensus and persist-
ent disagreement in order to progress the discussion
constructively.
Sessions with policy advisors will be facilitated by the
project’s Chief Investigators, who will play a dual role in
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mation regarding the process and its outcomes.
Facilitators drew on micro- and meso-level research
questions to inform the specific topics of case studies. At
the beginning of each session and throughout the discus-
sion, participants were asked to consider specific questions,
with participants in the ARTcase study being asked, for ex-
ample: ‘Should the criteria for public funding of IVF be
changed? If yes, how and why? If no, why?’; and those par-
ticipating in the B12/folate case study: ‘What things should
be considered when making decisions about how much we
should publicly subsidise B12/folate pathology tests?’
Meta-questions regarding the barriers and facilitators to
disinvestment more generally and the role of various stake-
holders in health policy decision-making were also
explored with each group. Supplementary questions varied
according to the participant’s role (clinician, consumer, citi-
zen (community), policy advisor) and time was allowed for
open, participant-driven discussion.
Members of the community, consumer, and clinical
engagement groups were offered a small honorarium for
each session they attended in order to cover any
expenses associated with their participation. Policy advi-
sors will not be offered an honorarium for their partici-
pation, because it is considered that consultations of this
nature align with current government activity and thus
fall within the remit of their professional roles.
Data collection and analysis
Given the dual research/policy development objectives
of this project, collection and dissemination of both the
deliberative and analytical outputs of the stakeholder
engagements were considered critical [22]. That is, our
analysis is set to generate both a thematic representation
of the content of deliberations, as well as more meta-
level discussion around the ideological and material
implications of the arguments and values articulated.
After obtaining consent from participants, delibera-
tions were audio-recorded and transcribed verbatim by
an experienced Hansard reporter (all speech machine
typed in full as opposed to shorthand in real time). This
occurred contemporaneously for all engagements.
The research component of the project demands that
the content of participants’ deliberations be analysed
in order to examine the social processes of negotiation
and practical reasoning inherent in disinvestment deci-
sion-making. As such, the transcripts will be analysed
using a synthetic approach to discourse analysis [25],
combining the traditions of conversation analysis/
ethnomethodology with an interest in broader cultural
and historical power relations [26]. This approach
allows a focus on the structure of participants’
accounts (how they were put together rhetorically so
as to appear credible or persuasive in the deliberative
context) as well as their function in justifying broader
disinvestment outcomes.
Deliberative outputs of the process will be reviewed
and discussed by the research staff with reference to
the transcripts, in addition to the notes, lists, and
other written outputs produced by the participants. Be-
cause pre-formulated options (requiring only a consen-
sus ‘yes/no’ decision) were not offered to the
participants, a singular, consensual ‘outcome’ of the de-
liberation may not be immediately (or ever) evident.
For example, in preliminary analyses we see that parti-
cipants revised their positions over the course of the
discussions. This appears particularly evident in
engagements with community groups, and requires
that the report detailing the deliberative output of this
group be endorsed by the participants after the con-
clusion of deliberation.
Costs
Table 3 details the expenses associated with the engage-
ment components of each case study (completed at the
Table 3 Summary of expenses associated with
stakeholder engagements (all costs are in Australian
Dollard, incurred over 2009 to 2012)
Expense category ART case study B12/folate
case study
Total
Honoraria $7,849 $11,231 $19,080
Participant recruitment $3,653 $3,500 $7,153
Venue
> Food and drinks (inc.
room hire)
$7,293 $9,887 $17,180
> Equipment hire - $427 $427
Expert witnesses $7,040 $9,152 $16,192
Facilitation $6,978 $3,600 $10,578
> Facilitation associated
costs
$5,608 $2,622 $8,229
Stenography $7,514 $6,913 $14,427
Flights
> Participant - $1,663 $1,663
> Research $2,474 $2,752 $5,226
Accommodation
> Participant - $160 $160
> Research $350 $803 $1,153
Project management $4,800 $4,800 9,600
Staff salaries (administrative
support*)
$35,000 $35,000 $70,000
Other operating costs $1,945 $531 $2,476
Total $90,504 $93,041 $183,544
* Does not include research staffing costs for the development of systematic
review evidence, costings and ethical analyses, or supervision time by Chief
Investigators.
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depend on the purpose, context, and extent of engage-
ment. Although these costs may appear large at first
sight, they are small compared to the cost implications
of continued use (or otherwise) of the relevant technolo-
gies. The costs associated with undertaking the system-
atic reviews on which the stakeholder engagements are
based are not included in this summary, nor is the time
of lead study investigators.
Discussion
Drawing on the strengths of health technology assess-
ment and deliberative democratic theory, this program
of research attempts to create replicable processes for
both governments and private payers to develop trans-
parent, evidence-based policy decisions in the domain of
disinvestment.
Systematic review is well-accepted in Australian health
policy decision-making, particularly as a component of
health technology assessment. We are interested if sys-
tematic review will be seen as equally crucial to precede
disinvestment decisions, possibly by reducing informa-
tion asymmetry between policy advisors and clinical and
other stakeholder groups.
We hypothesise that the deliberative engagement with
the community will be seen to add valuable information to
a policy decision, helping to balance the vested interests of
single-issue consumer groups. However, it may be that the
outcomes of engagement with partisan stakeholders (clini-
cians and consumers) are viewed with more caution; an as-
sessment of the value of engaging with these groups will be
an important outcome of this process.
At the time of writing, the program has been success-
ful in engaging a wide range of stakeholders in con-
structive and wide-ranging deliberations. Analysis of the
varied outputs of the deliberative engagements will con-
tribute to the methodological development around how
to best integrate scientific and colloquial evidence for
consideration by policy advisors and may contribute to
the legitimization of broad and transparent stakeholder
engagement in this context.
Embedding disinvestment research more firmly within
the established domain of quality and safety may re-
orientate these discussions towards provision of the
most effective care, facilitate more transparent discus-
sions, and help alleviate the incorrect perception that
disinvestment is a process of rationing.
From a process perspective, there are clear challenges
in recruiting appropriate stakeholder groups, informing
deliberations in a neutral manner and supporting active
deliberation. Stakeholder groups will vary across tech-
nologies and procedures examined, and it is unlikely that
a ‘one size fits all’ approach to the undertaking of a
process such as this will be appropriate. There remains a
role for policy makers to further define the parameters of
stakeholder engagement that they will accept as making a
legitimate contribution to policy development, and this
study hopes to progress this. In doing this though, it is crit-
ical that this type of process not be used as a form of ‘mar-
ket research,’ or to retrospectively justify policy decisions.
This work is situated at the intersection of health pol-
icy, health technology assessment, and deliberative dem-
ocracy. As such, it is theoretically possible to evaluate it
from a number of perspectives; the outcomes can be
variously defined and evaluated. While the ultimate out-
come of this work may appear to be a disinvestment de-
cision for each of the case studies (removal or restriction
of funding), this overlooks the fact that a change of such
magnitude is reliant on multiple actors and processes
outside the bounds of the research sphere; the re-
searcher is not the implementer of policy change. As
such, failure to implement an actual disinvestment deci-
sion from policy groups should not be considered a fail-
ure of this process. However, as this project is designed
to contribute pragmatically to policy development (in
both the public and private funding domains), it is con-
sidered that those actively involved in the development
of health funding policy in Australia are in a unique pos-
ition to evaluate the project’s outputs.
As such, senior policy advisors within state and federal
levels of government across multiple relevant portfolios will
be approached for their views on the usefulness of the
process, its further development, and how the individual
components, alongside the deliberative and analytical out-
puts, might contribute to disinvestment policy development.
We will attempt to uncover from policy advisors what
they consider to be the evidentiary requirements for dis-
investment processes. They will also be asked to con-
sider—from resource and priority points of view—the
desirability and practicality of applying this process
across the large number of publicly funded procedures
in Australia and the necessary and sufficient conditions
that would be required for full or partial disinvestment
to be enacted. Views on the processes’ limitations will
also be explicitly sought from policy advisors.
While participatory processes hold great promise for
their potential to offer a diversity of knowledge and ex-
perience to the policy-making process, they do not rep-
resent any guarantee of creating a smoother, less
contentious policy process. However, when coverage
decisions contain significant moral dimensions and
dilemmatic elements, decision making may indeed bene-
fit from the experiential knowledge delivered through
informed deliberation with engaged stakeholders.
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